Expert Interview
A third look at Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, and the results from the Phase 2 Venture trial of VK2735
Ticker(s): VKTX
Institution Private Practice
- Endocrinologist
- treats 63 pediatrics patients with growth hormone deficiency
- familiar with the results from the Phase 3 study of NGENLA (somatrogon-ghla) vs somatropin in treatment-naïve children with growth hormone deficiency
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
